Clinical Trial Update: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pomalidomide alone or with low-dose dexamethasone in relapsed/refractory multiple myeloma, reporting maximum tolerated dose, safety, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-04-25